![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 43, 44311-44319, October 22, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

¶







From the
Departments of
Biochemistry and Molecular Biology,
Otolaryngology/Head and Neck Surgery, and ||Medicine and the Ralph H. Johnson Veterans Affairs Medical Center, Medical University of South Carolina, Charleston, South Carolina 29425, the **Louisiana State University Health Sciences Center, Department of Biochemistry and Molecular Biology, New Orleans, Louisiana 70112, and ¶Abant Izzet Baysal University, Izzet Baysal Medical Faculty, Department of Otolaryngology, Bolu, Turkey
In this study, endogenous long chain ceramides were measured in 32 human head and neck squamous cell carcinoma (HNSCC) and 10 nonsquamous head and neck carcinoma tumor tissues, as compared with adjacent noncancerous tissues, by liquid chromatography/mass spectroscopy. Interestingly, only one specific ceramide, C18:0-ceramide, was selectively down-regulated in the majority of HNSCC tumor tissues. On the other hand, in nonsquamous tumor tissues, this selectivity for C18-ceramide was not detected. These data suggested the hypotheses that decreased levels of C -ceramide might impart a growth advantage to HNSCC 18cells and that increased generation of C18-ceramide may be involved in the inhibition of growth. These roles were examined by reconstitution of C18-ceramide at physiologically relevant concentrations in UM-SCC-22A cells (squamous cell carcinoma of hypopharynx) via overexpression of mammalian upstream regulator of growth and differentiation factor 1 (mUOG1), a mouse homologue of longevity assurance gene 1 (mLAG1), which has been shown to specifically induce the generation of C18-ceramide. Liquid chromatography/mass spectroscopy analysis showed that overexpression of the mLAG1/mUOG1 resulted in increased levels of only C18:0-ceramide by
2-fold, i.e. concentrations similar to those of normal head and neck tissues. Importantly, increased generation of C18-ceramide by mLAG1/mUOG1 inhibited cell growth (
7080%), which mechanistically involved the modulation of telomerase activity and induction of apoptotic cell death by mitochondrial dysfunction. In conclusion, this study demonstrates, for the first time, a biological role for LAG1 and C18-ceramide in the regulation of growth of HNSCC.
Received for publication, June 21, 2004 , and in revised form, July 26, 2004.
* This work was supported by National Institutes of Health Grants CA-88932 (to B. O.), AG-16583 (to L. M. O.), AG06168 (to S. M. J.), and CA-097132 (to Y. A. H.) and by funds from the Department of Defense (Phase VI program project through the Hollings Cancer Center) (to B. O.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. E-mail: ogretmen{at}musc.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
C. Shah, G. Yang, I. Lee, J. Bielawski, Y. A. Hannun, and F. Samad Protection from High Fat Diet-induced Increase in Ceramide in Mice Lacking Plasminogen Activator Inhibitor 1 J. Biol. Chem., May 16, 2008; 283(20): 13538 - 13548. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Corcoran, Q. He, S. Ponnusamy, B. Ogretmen, Y. Huang, and M. S. Sheikh Neutral Sphingomyelinase-3 Is a DNA Damage and Nongenotoxic Stress-Regulated Gene That Is Deregulated in Human Malignancies Mol. Cancer Res., May 1, 2008; 6(5): 795 - 807. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Laviad, L. Albee, I. Pankova-Kholmyansky, S. Epstein, H. Park, A. H. Merrill Jr., and A. H. Futerman Characterization of Ceramide Synthase 2: TISSUE DISTRIBUTION, SUBSTRATE SPECIFICITY, AND INHIBITION BY SPHINGOSINE 1-PHOSPHATE J. Biol. Chem., February 29, 2008; 283(9): 5677 - 5684. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Wooten-Blanks, P. Song, C. E. Senkal, and B. Ogretmen Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1 FASEB J, October 1, 2007; 21(12): 3386 - 3397. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Yu, S. A. Novgorodov, D. Chudakova, H. Zhu, A. Bielawska, J. Bielawski, L. M. Obeid, M. S. Kindy, and T. I. Gudz JNK3 Signaling Pathway Activates Ceramide Synthase Leading to Mitochondrial Dysfunction J. Biol. Chem., August 31, 2007; 282(35): 25940 - 25949. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Min, A. Mesika, M. Sivaguru, P. P. Van Veldhoven, H. Alexander, A. H. Futerman, and S. Alexander (Dihydro)ceramide Synthase 1 Regulated Sensitivity to Cisplatin Is Associated with the Activation of p38 Mitogen-Activated Protein Kinase and Is Abrogated by Sphingosine Kinase 1 Mol. Cancer Res., August 1, 2007; 5(8): 801 - 812. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Baran, A. Salas, C. E. Senkal, U. Gunduz, J. Bielawski, L. M. Obeid, and B. Ogretmen Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells J. Biol. Chem., April 13, 2007; 282(15): 10922 - 10934. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Senkal, S. Ponnusamy, M. J. Rossi, J. Bialewski, D. Sinha, J. C. Jiang, S. M. Jazwinski, Y. A. Hannun, and B. Ogretmen Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas Mol. Cancer Ther., February 1, 2007; 6(2): 712 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Pewzner-Jung, S. Ben-Dor, and A. H. Futerman When Do Lasses (Longevity Assurance Genes) Become CerS (Ceramide Synthases)?: INSIGHTS INTO THE REGULATION OF CERAMIDE SYNTHESIS J. Biol. Chem., September 1, 2006; 281(35): 25001 - 25005. [Full Text] [PDF] |
||||
![]() |
X. L. Guan, X. He, W.-Y. Ong, W. K. Yeo, G. Shui, and M. R. Wenk Non-targeted profiling of lipids during kainate-induced neuronal injury FASEB J, June 1, 2006; 20(8): 1152 - 1161. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. E. Senkal, S. Ponnusamy, M. J. Rossi, K. Sundararaj, Z. Szulc, J. Bielawski, A. Bielawska, M. Meyer, B. Cobanoglu, S. Koybasi, et al. Potent Antitumor Activity of a Novel Cationic Pyridinium-Ceramide Alone or in Combination with Gemcitabine against Human Head and Neck Squamous Cell Carcinomas in Vitro and in Vivo J. Pharmacol. Exp. Ther., June 1, 2006; 317(3): 1188 - 1199. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Schulz, T. Mousallem, M. Venkataramani, D.-A. Persaud-Sawin, A. Zucker, C. Luberto, A. Bielawska, J. Bielawski, J. C. M. Holthuis, S. M. Jazwinski, et al. The CLN9 Protein, a Regulator of Dihydroceramide Synthase J. Biol. Chem., February 3, 2006; 281(5): 2784 - 2794. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Lahiri and A. H. Futerman LASS5 Is a Bona Fide Dihydroceramide Synthase That Selectively Utilizes Palmitoyl-CoA as Acyl Donor J. Biol. Chem., October 7, 2005; 280(40): 33735 - 33738. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Voelkel-Johnson, Y. A. Hannun, and A. El-Zawahry Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein Mol. Cancer Ther., September 1, 2005; 4(9): 1320 - 1327. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |